BioCentury
ARTICLE | Company News

Actelion gains after boosting guidance

April 22, 2015 2:19 AM UTC

Actelion Ltd. (SIX:ATLN) gained CHF6.10 to CHF123 on Tuesday after reporting earnings and raising its 2015 guidance. The company now expects core earnings growth in the low double digits, at constant exchange rates and excluding benefits derived from the reversals of U.S. rebates on its drugs. In February, it had expected low single-digit growth.

The company reported CHF95 million ($100 million) in sales of Opsumit macitentan in 1Q15, up from CHF68 million ($73.1 million) in 4Q14. The tissue-targeting endothelin receptor antagonist to treat pulmonary arterial hypertension (PAH) generated CHF180 million ($193.4 million) in sales during 2014, its first full year on the market. ...